[{"id":"577a4268-ea8b-44ef-b557-7019f2e329c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05691504","created_at":"2023-01-20T16:00:14.081Z","updated_at":"2025-02-25T16:46:30.558Z","phase":"Phase 1","brief_title":"Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers","source_id_and_acronym":"NCT05691504","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • BCL2L1","pipe":"","alterations":" ","tags":["BRAF • BCL2L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cotellic (cobimetinib) • pelcitoclax (APG-1252)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 09/14/2023","start_date":" 09/14/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-05"},{"id":"721fdaab-3a1b-4137-ac76-da3bdf51d631","acronym":"","url":"https://clinicaltrials.gov/study/NCT04893759","created_at":"2021-05-19T11:52:44.705Z","updated_at":"2024-07-02T16:35:22.677Z","phase":"Phase 1","brief_title":"A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors","source_id_and_acronym":"NCT04893759","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" BCL2L2","pipe":"","alterations":" ","tags":["BCL2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pelcitoclax (APG-1252)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/06/2022","start_date":" 01/06/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-01-23"},{"id":"00d40478-682a-4afc-87d8-0de2d98dbcc1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03080311","created_at":"2021-01-18T15:10:26.131Z","updated_at":"2024-07-02T16:36:07.402Z","phase":"Phase 1","brief_title":"A Study of APG-1252 in Patients With SCLC or Other Solid Tumors","source_id_and_acronym":"NCT03080311","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" BCL2L2","pipe":"","alterations":" ","tags":["BCL2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pelcitoclax (APG-1252)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 02/12/2017","start_date":" 02/12/2017","primary_txt":" Primary completion: 06/22/2020","primary_completion_date":" 06/22/2020","study_txt":" Completion: 07/17/2020","study_completion_date":" 07/17/2020","last_update_posted":"2022-07-12"}]